Peptides for leaky gut FAQ

BPC-157 demonstrates oral bioavailability in gastric environments, though small intestine targeting requires higher doses. Research suggests 3–5× the subcutaneous dose orally to achieve equivalent mucosal effects. KPV's tripeptide structure allows liposomal or nanoparticle encapsulation for oral delivery, though commercial formulations meeting pharmaceutical purity standards remain limited. Thymosin Alpha-1 lacks oral bioavailability entirely due to rapid enzymatic degradation. For injection-averse patients, BPC-157 oral + dietary intervention represents the most evidence-backed non-injection approach, accepting longer timelines for barrier restoration.

Temporary symptom exacerbation during NF-κB inhibition can occur as bacterial endotoxin clearance increases. When KPV reduces intestinal inflammation, previously sequestered LPS (lipopolysaccharide) in inflamed tissue gets mobilised into lymphatic circulation before liver clearance. Creating transient endotoxemia symptoms (fatigue, brain fog, low-grade fever). This typically resolves within 5–7 days as hepatic detoxification catches up. If symptoms persist beyond two weeks or worsen progressively, discontinue and evaluate for underlying infection or SIBO that KPV's anti-inflammatory effects may be masking.